Expanding Frontiers in Cancer Treatment: RyboDyn Collaborates with Moffitt Cancer Center

RyboDyn, Inc., a biotechnology company based in San Diego, has recently announced an expansion of its partnership with the renowned Moffitt Cancer Center, a leader in cancer care and research. This collaboration is designed to fast-track the development of innovative immunotherapies, targeting a new class of cancer-specific proteins detected through RyboDyn's advanced sequencing technology, RyboCypher™.

Earlier this year, RyboDyn revealed a breakthrough discovery of a class of proteins derived from less-studied RNA species, termed Dark Targets™. These antigens are not easily detectable with traditional methods, presenting a largely uncharted territory for drug development in oncology. By extending its collaboration with Moffitt, RyboDyn intends to validate the existence and therapeutic promise of these Dark Targets™ across various tumor types, utilizing Moffitt’s extensive tumor repository, which is among the most comprehensive in the world.

Dr. Alex Jaeger from Moffitt's Molecular Oncology Department emphasized the importance of Moffitt's tumor bank in confirming novel targets across diverse cancer patients. “The correlation of molecular signals with detailed clinical metadata significantly accelerates both discovery and translational development,” he stated.

The initial findings from this partnership have indicated that certain Dark Targets™ are regularly presented on tumor cells but remain absent in normal tissues. This discovery significantly reduces the risks associated with the development of therapies targeting these specific cancers. Corey Dambacher, RyboDyn’s President and CTO, expressed optimism about the consistency of these findings, indicating that the presence of these targets in actual patient samples lends significant credibility to their relevance.

It is acknowledged that while not every Dark Target™ is exclusive to cancer, a unique subset appears consistently on tumor cells. This distinction makes them attractive prospects for therapeutic innovation.

“We are not creating a personalized medicine platform; instead, we’re designing therapies that blend precision with scalability” said Imad Ajjawi, CEO of RyboDyn. “By honing in on targets that are conserved with clear tumor-specific characteristics, we are opening avenues for scalable, ready-to-use therapies in oncology.”

Dr. Alex Jaeger remarked on the collaborative effort as a testament to a shared vision of advancing cancer immunotherapies. By merging Moffitt's clinical expertise with RyboDyn's pioneering discovery methods, they aim to fast-track the journey towards more precise and effective treatment options.

About RyboDyn

Established in San Diego, California, RyboDyn, Inc. is at the forefront of developing groundbreaking immunotherapies directed at the dark genome. Leveraging its proprietary sequencing technology coupled with AI-enabled bioinformatics, RyboDyn is revealing and validating previously unnoticed proteins and disease-specific targets through a unique “targets-to-assets” therapeutic development approach.

The firm collaborates with leading clinical institutions and biopharma partners to authenticate and propel its drug development pipeline, aiming to provide transformative solutions for cancer and other diseases that currently lack effective treatments. For additional information, visit RyboDyn's website or reach out via email for inquiries.